Filter Results:
(527)
Show Results For
- All HBS Web
(527)
- People (2)
- News (139)
- Research (128)
- Events (2)
- Multimedia (6)
- Faculty Publications (70)
Show Results For
- All HBS Web
(527)
- People (2)
- News (139)
- Research (128)
- Events (2)
- Multimedia (6)
- Faculty Publications (70)
Page 1 of 527
Results →
- September 2003 (Revised March 2007)
- Case
Direvo Biotech AG
Describes the financing and growth decisions facing Direvo, a young German biotech firm with a customer/partner that wants to become an investor. Also discusses the business model for Direvo's directed evolution technology, with applications in both industrial enzymes... View Details
Keywords: Business Model; Decisions; Business Exit or Shutdown; Value; Business Startups; Biotechnology Industry; Germany
Roberts, Michael J., Vincent Dessain, and Anders Sjoman. "Direvo Biotech AG." Harvard Business School Case 804-017, September 2003. (Revised March 2007.)
- 12 Jan 2009
- News
Biotech Blues
- 07 Aug 2000
- Research & Ideas
The Business of Biotech
With the sequencing of the human genome running ahead of schedule, the American Stock Exchange's "BTK" biotech index registered an annual increase of 232 percent in February, prompting exuberant headlines ("Move Over,... View Details
- 01 Jun 2000
- News
The Business of Biotech
With the sequencing of the human genome running ahead of schedule (see sidebar), the American Stock Exchange's "BTK" biotech index registered an annual increase of 232 percent in February, prompting exuberant headlines ("Move Over,... View Details
Keywords: Julia Hanna
- 18 Sep 2013
- News
The 10 most influential women in biotech
- 23 Jul 2001
- Research & Ideas
How Relationships are Building Biotech
Creativity (Oxford University Press) spells it all out. The Missing Link Higgins became interested in this missing link after watching a young biotech company go through two public offerings in the early 1990s. The observations she made... View Details
Keywords: by Martha Lagace & Mallory Stark
- June 3, 2010
- Article
Can Biotech Survive Icahn
By: Bill George
Keywords: Biotechnology Industry
George, Bill. "Can Biotech Survive Icahn." New York Times (June 3, 2010).
- December 2006 (Revised October 2007)
- Case
Monsanto: Realizing Biotech Value in Brazil
By: David E. Bell and Mary L. Shelman
In 2003, Monsanto's patented "Roundup Ready" technology was used illegally on 70-80% of the soybean area in southern Brazil. Under pressure from U.S. soybean growers, who were paying to license the technology, the firm implemented an innovative delivery-based... View Details
Keywords: Plant-Based Agribusiness; Patents; Lawfulness; Emerging Markets; Product Development; Agriculture and Agribusiness Industry; Biotechnology Industry; Brazil
Bell, David E., and Mary L. Shelman. "Monsanto: Realizing Biotech Value in Brazil." Harvard Business School Case 507-018, December 2006. (Revised October 2007.)
- January 2007
- Background Note
Note on Biotech Business Development
By: Richard G. Hamermesh and Robert F. Higgins
Describes the business development process in biotechnology companies. Topics covered include: participants in the licensing process and their interests, the major steps in the licensing process, the terms that are part of most agreements, and the most contentious... View Details
Keywords: Agreements and Arrangements; Entrepreneurship; Intellectual Property; Biotechnology Industry
Hamermesh, Richard G., and Robert F. Higgins. "Note on Biotech Business Development." Harvard Business School Background Note 807-032, January 2007.
- 08 Dec 2003
- Research & Ideas
Why Europe Lags in Pharmaceuticals and Biotech
Governmental, academic, and cultural differences are hurting Europe's chances of creating more competitive pharmaceutical and biotech industries—and not much hope is on the horizon, according to a panel of experts at the 2003 HBS European... View Details
- December 2005 (Revised August 2006)
- Case
Amgen Inc.'s Epogen--Commercializing the First Biotech Blockbuster Drug
By: Felix Oberholzer-Gee and Dennis A. Yao
Amgen Inc.'s Epogen was the first biotech blockbuster drug. Epogen helped prevent anemia, a condition that leads to severe fatigue, increased risk of cardiovascular disease, and even death. At the time, the market for Epogen, which included dialysis patients and... View Details
Keywords: Health Care and Treatment; Strategic Planning; Competition; Patents; Innovation and Invention; Pharmaceutical Industry; Biotechnology Industry; United States
Oberholzer-Gee, Felix, and Dennis A. Yao. "Amgen Inc.'s Epogen--Commercializing the First Biotech Blockbuster Drug." Harvard Business School Case 706-454, December 2005. (Revised August 2006.)
- 09 Oct 2020
- Blog Post
4 Things To Know About the MS/MBA Biotech
other’s experiences and maintain a tight-knit community from which we can learn every day. 2. The program is for those passionate about health care and life sciences I also expected that most people in my cohort would be solely interested in being a CEO of the next big... View Details
- 01 May 2008
- News
Biotech Focus: Chasing the Pot of Gold
- 10 Jun 2022
- News
Building an AI-First Biotech Company
- 12 Sep 2003
- News
Biotech summit draws 100 industry leaders
- 04 Jun 2010
- News
Another View: Can Biotech Survive Icahn?
- 13 Jan 2021
- Video
Nora Rabah (MS/MBA Biotech 2022): Introduction
- 13 Jan 2003
- Research & Ideas
Making Biotech Work as a Business
create safer and more effective treatments and, of course, reap profits—industry executives, like hopeful patients, still restlessly wait for relief. Given its scientific potential, said Pisano, biotech continues to bump against several... View Details